Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Triple Negative Breast Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 223Carboplatin 218Cisplatin 205Paclitaxel 182Gemcitabine 149Docetaxel 127Capecitabine 114Dexamethasone 102Pemetrexed 101Cyclophosphamide 101Specimen Handling 99Magnetic Resonance Spectroscopy 97Oxaliplatin 96Radiotherapy 95Doxorubicin 91Fluorouracil 87Bevacizumab 83Nivolumab 74Leucovorin 72Rituximab 70Vincristine 67durvalumab 66Lenalidomide 63Etoposide 62atezolizumab 61Radiation 61Irinotecan 60130-nm albumin-bound paclitaxel 57Prednisone 56Letrozole 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Moxifloxacin × 1 year × Clear all
NCT04722978 2025-12-17

Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer

Sun Yat-sen University

Phase 3 Recruiting
228 enrolled
Breast

Triple Negative Breast Neoplasms

NCT05114720 2025-12-17

Moxifloxacin in Adjuvant Treatment of Patients With Operable Breast Cancer

Sun Yat-sen University

Phase 3 Completed
559 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡